Immunex' IL-4R "Safe" In Mild Asthma
Immunex' soluble Interleukin-4 receptor has been shown to be safe intreating patients with asthma, according to Phase I trial data presented at the American Academy of Allergy, Asthma and Immunology meeting in San Francisco, USA.
Of the 16 mildly asthmatic patients enrolled on the study, which was not placebo-contolled, 69% reported a decrease in asthma symptoms, including wheezing and coughing, following inhalation of a single dose of IL-4R and a follow up of seven days.
IL-4R was found to be safe and well-tolerated at all the five doses tested. There were also "hints of biologic response," said the company, which it plans to evaluate in further trials. Additional Phase I/II trials are being conducted to investigate the safety, efficacy and optimal administration of IL-4R for the treatment of allergic asthma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze